A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people lose weight.
- Who can join
- Adults 18 to 64, have obesity or are overweight.
- What you take
- Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 3 years.
- What you get
- Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
What this study is for
Primary condition: Obesity & Overweight. Also studied in: Weight Loss, Preventative Health, Body Weight, Cardiovascular Disease Risk Factor.
Full scientific study title: GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study.
Who can join
Adults 18 to 64, have obesity or are overweight. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Speaks English
- Community-dwelling, community-living status
- Able to ambulate independently, with or without aids or devices
- Unless medically indicated, willingness to stay on current program for 12 months and participate in all study activities
- Provides informed consent for study participation
Key exclusion criteria
- Study screener completed more than 11 days after Noom program enrollment if participating in a Noom program (GLP-1 programs, Noom Weight, and Free Tier)
- GLP-1 use in the last 24 weeks (prior to Noom program enrollment if in GLP-1 arm)
- Female who is pregnant, breast-feeding, or intends to become pregnant during the 12-month program
- Previous or planned (during the 12-month study) bariatric surgery
- Active eating disorder
Where this trial runs
This trial has 1 sites across 1 state. Site contacts are listed for reference. They are not screening through this trial right now.
New Jersey1 site
- Noom, Inc.Princeton, New Jersey
Timeline
Scheduled start: April 30, 2026. Expected completion: May 2029. Last updated on ClinicalTrials.gov: May 15, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
